EGFR is frequently overexpressed or dysregulated in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), and glioblastoma, where it promotes tumorigenesis and correlates with poor prognosis [113,114,115,116,117]. This evidence concerns the gene EGFR and glioblastoma.